IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 1 9 2001

In re Patent Application of

MÜLLER et al.

Serial No.

09/912,414

Filed:

July 26, 2001

For:

TRANSCRIPTION FACTOR E2F DNA-BINDING DOMAIN

INHIBITOR PEPTIDES AND THEIR USE

November 19, 2001

Atty. Ref.:

Examiner:

Group:

620-151

Assistant Commissioner for Patents Washington, DC 20231

Sir:

STATEMENT

The attached paper and computer-readable copies of the Sequence Listing are the same. No new matter has been added.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

B. J. Sadoff

Reg. No. 36,663

BJS:eaw

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

NUV 1 9 2001 5

SEQUENCE LISTING

<110> Müller, Rolf Kontermann, Roland E Montigiani, Silvia <120> Transcription factor E2F DNA-binding domain inhibitor peptides and their use <130> 620-151 <140> US 09/912,414 <141> 2001-07-26 <150> PCT/GB00/00227 <151> 2000-01-26 <150> GB 9901710.5 <151> 1999-01-26 <160> 40 <170> PatentIn Ver. 2.1 <210> 1 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 1 Phe Trp Leu Arg Phe Thr 1 <210> 2 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide

<400> 2

1

Trp Val Arg Trp His Phe

```
<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 3
Trp His Phe Ile Phe Trp
<210> 4
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 4
Ile Trp Leu Ser Gly Leu Ser Arg Gly Val Trp Val Ser Phe Pro
                  5
<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 5
Gly Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
 1
                 5
                                     10
<210> 6
<211> 16
<212> PRT
<213> Drosophila melanogaster
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
  1
                  5
                                     10
                                                          15
```

```
<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (1)
<223> In Claims 1 & 2, Xaa is an amino terminal or a sequence of from 1
      to 4 amino acids
<220>
<221> SITE
<222> (1)
<223> In Claim 3, Xaa is an amino terminal or a sequence of from {\bf 1}
      to 4 amino acids each of which are selected from Gly, Ala, Ile, Leu,
      Val, Ser, Thr, Lys, or Arg
<220>
<221> SITE
<222> (2)
<223> In Claim 1, Xaa is an aromatic amino acid
<220>
<221> SITE
<222> (2)
<223> In Claims 2 and 3, Xaa is Phe or Trp
<220>
<221> SITE
<222> (3)
<223> In Claims 1 & 2, Xaa is from two to four amino acids
<220>
<221> SITE
<222> (3)
<223> In Claim 3, Xaa is from two to four amino acids each of which are
      selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His or Phe
<220>
<221> SITE
<222> (4)
<223> In Claim 1, Xaa is an aromatic amino acid
<220>
<221> SITE
<222>(4)
<223> In Claim 2, Xaa is Phe or Trp
<220>
<221> SITE
<222> (4)
<223> In Claim 3, Xaa is Trp
```

```
<220>
<221> SITE
<222> (5)
<223> In Claims 1 & 2, Xaa is a carboxy terminal or a sequence of from
      one to four amino acids
<220>
<221> SITE
<222>(5)
<223> In Claim 3, Xaa is a carboxy terminal or a sequence of from
      one to four amino acids each of which are selected from Gly, Ala,
Ile,
      Leu, Val, Ser, Thr, Lys, Arg, His, Phe or Tyr
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 7
Xaa Xaa Xaa Xaa
  1
<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (2)..(3), (5)..(6)
<223> Each Xaa is independently any amino acid
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 8
Trp Xaa Xaa Trp Xaa Xaa
<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (2)..(3), (5)
<223> Each Xaa is independently any amino acid selected
      from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg,
      His, or Phe
```

```
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 9
Trp Xaa Xaa Trp Xaa Phe
<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (2)..(3), (5), (7)..(8)
<223> Each Xaa is independently any amino acid selected
      from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg,
      His, or Phe
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 10
Trp Xaa Xaa Trp Xaa Phe Xaa Xaa Trp
 1
<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (2)..(3)
<223> Each Xaa is independently any amino acid selected
      from Gly, Ala, Ile, Leu, Val, Ser, Thr, or Arg
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 11
Trp Xaa Xaa Trp His Phe
  1
                  5
```

```
<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (1)..(2), (4)..(7)
<223> Each Xaa is independently any amino acid
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 12
Xaa Xaa Phe Xaa Xaa Xaa Trp
  1
                  5
<210> 13
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (1)..(2), (4)..(7)
<223> Each Xaa is independently any amino acid selected
      from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg,
      His, Phe, or Tyr
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 13
Xaa Xaa Phe Xaa Xaa Xaa Trp
 1
<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (1)..(2)
<223> Each Xaa is independently any amino acid selected
      from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg,
      His, Phe, or Tyr
```

```
<220>
<221> SITE
<222> (5)
<223> Xaa is independently any amino acid selected from
      Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His,
      Phe, or Tyr
<220>
<221> SITE
<222> (6)
<223> Xaa is independently any amino acid selected from
      Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His,
      Phe, or Tyr
<220>
<221> SITE
<222> (7)
<223> Xaa is independently any amino acid selected from
      Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His,
      Phe, or Tyr
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 14
Xaa Xaa Phe Arg Xaa Xaa Xaa Trp
  1
<210> 15
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> (1)
<223> Xaa is independently selected from the group Gly,
      Ala, Ile, Leu, Val, Ser, and Thr
<220>
<221> SITE
<222> (2)
<223> Xaa is independently selected from the group Gly,
      Ala, Ile, Leu, Val, Ser, and Thr
<220>
<221> SITE
<222> (5)
<223> Xaa is independently selected from the group Gly,
      Ala, Ile, Leu, Val, Ser, and Thr
```

```
<220>
<221> SITE
<222> (6)
<223> Xaa is independently selected from the group Gly,
      Ala, Ile, Leu, Val, Ser, and Thr
<220>
<221> SITE
<222> (7)
<223> Xaa is independently selected from the group Gly,
     Ala, Ile, Leu, Val, Ser, and Thr
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 15
Xaa Xaa Phe Arg Xaa Xaa Xaa Trp
  1
<210> 16
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      Oligonucleotide probe
<400> 16
                                                                    30
cgacgcgctt ggcgggagat agaaaagtgc
<210> 17
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      Oligonucleotide probe
<400> 17
                                                                    19
atttttctga tttggttaa
<210> 18
<211> 12
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      Oligonucleotide probe
```

```
<400> 18
atggggcgga ga
                                                                   12
<210> 19
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      Oligonucleotide probe
<400> 19
                                                                   26
cgccttgaat gacgtcaagg ccgcga
<210> 20
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 20
Ala Val Arg Trp His Phe
<210> 21
<211> 6
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 21
Trp Ala Arg Trp His Phe
 1
<210> 22
<211> 6
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
```

```
<400> 22
Trp Val Ala Trp His Phe
<210> 23
<211> 6
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 23
Trp Val Arg Ala His Phe
 1
<210> 24
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 24
Trp Val Arg Trp Ala Phe
<210> 25
<211> 6
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
     peptide
<400> 25
Trp Val Arg Trp His Ala
                 5
```

```
<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 26
Gly Ser Arg Ile Leu Thr Phe Arg Ser
<210> 27
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 27
Ile Leu Thr Phe Arg Ser Gly Ser Trp
  1
                  5
<210> 28
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 28
Phe Arg Gly Ser Trp Ala Ser
 1
                  5
<210> 29
<211> 11
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 29
Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
  1
                  5
                                      10
```

```
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 30
Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
<210> 31
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 31
Arg Ile Leu Thr Phe Arg Ser Gly Ser
 1
                  5
<210> 32
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr
                  5
                                      10
<210> 33
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
```

``

<210> 30

```
<400> 33
Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr
                  5
<210> 34
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 34
Gly Ser Ala Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
<210> 35
<211> 15
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 35
Gly Ser Arg Ile Leu Thr Ala Arg Ser Gly Ser Trp Tyr Ala Ser
                 5
 1
                                     10
<210> 36
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
     peptide
```

Gly Ser Arg Ile Leu Thr Phe Ala Ser Gly Ser Trp Tyr Ala Ser

10

15

٠.

```
<210> 37
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 37
Gly Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Ala Tyr Ala Ser
                                     10
<210> 38
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 38
Gly Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Ala Ala Ser
                  5
<210> 39
<211> 6
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 39
Ala Val Arg Ala His Phe
 1
<210> 40
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 40
Gly Ser Arg Ile Leu Thr Ala Arg Ser Gly Ser Ala Tyr Ala Ser
                                     10
```

~